1
Idorsia Announces Successful Completion of Share and Bond Offerings
Latest Clinical Development Pipeline Updates and FDA Approvals
Key Pipeline Assets and Indications
Idorsia's clinical development pipeline encompasses multiple therapeutic areas, including:
- Cardiovascular
- Endocrinology
- Gastroenterology
- Immunology
- Neurology
Recent Developments
The company's phase 2 asset, ACT-132577, a dual endothelin receptor antagonist, is covered by a collaboration agreement with Janssen Pharmaceuticals.
Idorsia recently announced that the US Food and Drug Administration (FDA) has approved MODIFY, an oral therapy for the treatment of excessive daytime sleepiness in adults with narcolepsy.
In addition, Idorsia has completed a successful offering of new shares and bonds, providing the company with additional capital for its pipeline development.
Looking Ahead
With the completion of these offerings, Idorsia is well-positioned to continue advancing its clinical pipeline and delivering innovative therapies to patients in need.
Comments